COLLEGE BUSINESS & TECHNOLOGY PARK, DUBLIN 15, L2
Reg. FD
Investor Presentation
Amended material disclosure
Shareholder votes
Segment Operating Income to Adjusted EBITDA Reconciliations
Names Dr. Marek J. Honczarenko as EVP and Chief Scientific Officer
Changes in Board, Management or Compensation
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
S-8 POS
Specialized Disclosure Report